TherapeuticsMD (TXMD) Announces $7M Private Placement of Preferred Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
TherapeuticsMD Announces Additional $7 Million Private Placement
October 31, 2022 6:50 AM EDTMaturity Date of Financing Agreement Extended to November 30, 2022
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), (TherapeuticsMD or the Company) an innovative, leading womens healthcare company, announced today that it received an additional $7 million private investment in the Companys Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital.
Under the terms of the Companys financing agreement with its lender, Sixth Street Specialty Lending, Inc. (Sixth Street), upon receipt of the investment and the delivery... More
